Pfizer debuts on-line site for PMC updates

Global drug giant Pfizer says that it has launched an on-line site to provide up-to-date, user-friendly information on the status of its US post-marketing surveillance commitments. Post-marketing studies are designed to provide additional information about a medicine's safety, efficacy or optimal use after it has received regulatory approval. This initiative is the first of its kind for a pharmaceutical company, claims Pfizer.

The web site provides study descriptions and status of Food and Drug Administration post-marketing commitments, current due dates, total listed Pfizer PMCs, and general information about the PMC process. It is now available at: www.pfizer.com/pmc.

"From a medical compound's discovery, through its development, and for as long as it is prescribed, each of our medicines undergoes thorough safety and efficacy monitoring and evaluation in collaboration with health authorities around the world," said Pfizer's chief medical officer Joseph Feczko. "This kind of transparency helps encourage patients to ask their physicians about treatment options. When these conversations happen, they often help patients better understand the risks and benefits of different treatment options," he added.